MOLLY POWELL: Open Payments
NPI 1811509482 · BERLIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$961 in 55 payments from 17 companies in 2025. Trend: 2023 $568 · 2024 $1,122 · 2025 $961
Food & beverage: $961
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $269 |
| ABBVIE INC. | 12 | $165 |
| AstraZeneca Pharmaceuticals LP | 7 | $155 |
| Lilly USA, LLC | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| PFIZER INC. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Exact Sciences Corporation | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
Products named: UBRELVY, Rybelsus, BREZTRI, Ozempic, FARXIGA, MOUNJARO, CAPLYTA, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
